Efficacy of long-term treatment with mepolizumab in severe eosinophilic asthma (case reports)

Abstract

Two clinical cases of severe eosinophilic asthma taking long-term therapy with mepolizumab (38 and 45 months are described in the article. Both the cases demonstrate the effectiveness of the drug both in allergic and non-allergic (aspirin-induced) asthma. Significant clinical improvement was achieved in both cases under the treatment with mepolizumab during ≥ 3 years. Important results of the treatment were improvement in symptoms of severe asthma, reduction in exacerbation rate, and, additionally, overcoming corticosteroid addiction in patients. The therapy with mepolizumab was highly safe.